Seres Therapeutics (MCRB) Tops Q3 EPS by 13c

Seres Therapeutics (NASDAQ: MCRB) reported Q3 EPS of ($0.37), $0.13 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $310 thousand versus the consensus estimate of $853 thousand.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Evolution Petroleum closes $16M Midland Basin royalty acquisition
• China semiconductor equipment imports grow 9% in July, Barclays comments